Tocagen Sets IPO Pricing Range

San Diego-based Tocagen, a clinical stage gene therapy company aiming at treating cancer, has set the pricing range for its IPO. The company said in a filing that it expects to offer 7,250,000 shares of its common stock at between $10.00 and $12.00 per share. The company has applied to list as TOCA on the NASDAQ Global Market. Tocagen's IPO is being underwritten by Leerink Partners, Evercore ISI, and Stifel. The company is backed by the Irwin Mark Jacobs and Joan Klein Jacobs Family Trust. Jacobs is the co-founder of Qualcomm.